N. R. Kuznetsova, G. P. Gaenko, S. V. Haidukov, N. V. Bovin, and E. L. Vodovozova1
ShemyakinOvchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences,
ul. Miklukho-Maklaya 16/10, Moscow, 117997 Russia
Received December 29, 2008; in final form, January 20, 2009
AbstractThe efficiency of the chemotherapeutic agent methotrexate (MTX) in cancer treatment is limited by
the frequent development of the drug resistance of tumor cells. We had previously shown in vitro using human
acute leukemia cells with various sensitivity to MTX (T-lymphoblastic CCRF-CEM line and resistant
CEM/MTX subline) that MTX incorporation into liposomes in the form of a lipophilic prodrug, diglyceride
conjugate (MTX-DG), allows for the overcoming of cell resistance due to the impaired active transmembrane
transport. In this work, we have studied the profile of binding with carbohydrates of the cell lines mentioned
using carbohydrate fluorescent probes (poly(acryl amide) conjugates). Lipophilic conjugates of tetrasaccharide
SiaLeX, 6'
HSO3LacNAc, and also inactive pentaol for incorporation into liposomes, have been synthesized.
The cytotoxicity of MTX-DG liposomes equipped with the SiaLeX ligand toward the sensitive CCRF-CEM cell
culture was demonstrated to be 3.5 times higher than that of MTX-DG liposomes bearing the control inactive
pentaol. The activity of MTX liposomes bearing 6'-HSO3LacNAc toward resistant CEM/MTX was 1.6-fold
increased. The use of carbohydrate ligands as molecular addresses for drug-carrying liposomes as a potential
method of treating heterogeneous tumor tissue is discussed.
Key words: glycoconjugates, lectins, leukemia, lipophilic prodrugs, liposomes, methotrexate, tumor cell resis-
tance
DOI: 10.1134/S1068162009040116
Pleiades Publishing home page | journal home page | top
If you have any problems with this server, contact webmaster.